Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
9.53 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Operating Activities: | |||||
| Net Income
| -135.352 | -108.501 | -73.958 | -35.879 | -7.74 |
| Depreciation & Amortization
| 6.222 | 3.745 | 2.132 | 0.537 | 0.072 |
| Deferred Income Tax
| -5.758 | 0 | 0.017 | 0 | 0 |
| Stock Based Compensation
| 16.669 | 11.664 | 5.2 | 0.354 | 0 |
| Change In Working Capital
| 72.466 | -2.134 | 6.286 | 4.255 | 1.771 |
| Accounts Receivables
| 0.002 | -0 | 0 | 0 | 0 |
| Inventory
| -0.002 | 0 | 0 | 0 | 0 |
| Accounts Payables
| 5.758 | -0.744 | -0.706 | 3.435 | 2.86 |
| Other Working Capital
| 66.708 | -1.39 | 6.992 | 0.82 | -1.089 |
| Other Non Cash Items
| 1.951 | 2.76 | 0.96 | 7.68 | -0.276 |
| Operating Cash Flow
| -43.802 | -92.466 | -59.363 | -23.053 | -6.173 |
| Investing Activities: | |||||
| Investments In Property Plant And Equipment
| -19.041 | -12.911 | -9.732 | -3.389 | -1.385 |
| Acquisitions Net
| 0.062 | 0.109 | 0.079 | 0 | 0 |
| Purchases Of Investments
| -103.151 | -384.417 | 0 | 0 | 0 |
| Sales Maturities Of Investments
| 210.931 | 178 | 0 | 0 | 0 |
| Other Investing Activites
| 0.108 | -0.206 | 0 | 0 | 0 |
| Investing Cash Flow
| 88.801 | -219.219 | -9.653 | -3.389 | -1.385 |
| Financing Activities: | |||||
| Debt Repayment
| 0 | 0 | 0 | 0 | -0.75 |
| Common Stock Issued
| 27.492 | 20.466 | 377.562 | 60.06 | 14.25 |
| Common Stock Repurchased
| 0 | 0 | 0 | -0.44 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| -0.116 | 20.466 | 377.562 | 0.44 | 0.75 |
| Financing Cash Flow
| 27.492 | 20.466 | 377.562 | 60.06 | 15 |
| Other Information: | |||||
| Effect Of Forex Changes On Cash
| -0.262 | 0 | 0 | 0 | 0 |
| Net Change In Cash
| 72.229 | -291.219 | 308.546 | 33.618 | 7.442 |
| Cash At End Of Period
| 128.101 | 60.19 | 351.409 | 42.863 | 9.245 |